2nd Sep 2013 07:00
2 September 2013 |
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Notice of Interim Results
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its interim results for the six months ended 30 June 2013 on Wednesday 11 September 2013.
A briefing for analysts will be held at 9.30am on the day of the results at the offices of Tavistock Communications, 131 Finsbury Pavement, London, EC2A 1NT.
- ends -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director | |
Tavistock Communications | Tel: +44 (0) 20 7920 3150 |
John West / Chris Munden / Andrew Dunn | |
Investec Bank plc (NOMAD) | Tel: +44 (0) 20 7597 5970 |
Gary Clarence / Daniel Adams / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$20 billion global wound care and wound closure market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.
AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer ("OEM") customers around the world, but the majority of the Group's revenues now come from its own brands - ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and haemostat products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.
AMS's products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.
With 450 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS's products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.
Related Shares:
Advanced Medical Solutions Group